-
Subject Areas on Research
-
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
-
A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
-
A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative.
-
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
-
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome.
-
Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
-
Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.
-
Antihyperlipidemic activity of amine cyanoboranes, amine carboxyboranes, and related compounds.
-
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
-
Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
-
Colestipol granules in the colon: macroscopic and microscopic findings.
-
Combination drug therapy for combined hyperlipidemia.
-
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation.
-
Countering clinical inertia in lipid management: Expert workshop summary.
-
Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers.
-
Dual hepatic metabolism of cerivastatin--clarifications.
-
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
-
Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
-
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
-
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
-
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
-
Effect of niacin on atherosclerotic cardiovascular disease.
-
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
-
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.
-
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.
-
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
-
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
-
Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life.
-
Evidence supporting secondary prevention strategies.
-
Extended-release niacin for modifying the lipoprotein profile.
-
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
-
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
-
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
-
Fenofibrate and diabetic retinopathy.
-
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
-
Focal toxicity of oxysterols in vascular smooth muscle cell culture. A model of the atherosclerotic core region.
-
High-dose statins in acute coronary syndromes.
-
Hypolipidemic activity of boronated nucleosides and nucleotides in rodents.
-
Hypolipidemic activity of tetrakis-mu-(trimethylamine-boranecarboxylato)-bis(trimethylamin e- carboxyborane)-dicopper(II) in rodents and its effect on lipid metabolism.
-
Identification and Characterization of Fenofibrate-Induced Liver Injury.
-
Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease.
-
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
-
Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications.
-
Influence of clinical trial participation on subsequent antithrombin use.
-
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
-
Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation.
-
Insurance status predicts acuity of thoracic aortic operations.
-
It's all connected.
-
JCL roundtable: Lipid treatment targets.
-
Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study.
-
Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE).
-
Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach.
-
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
-
Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry.
-
Lipoprotein(a) Testing Patterns in a Large Health System.
-
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
-
Management of diabetic retinopathy: a systematic review.
-
Medication oversupply in patients with diabetes.
-
Mixed messages on systemic therapies for diabetic retinopathy.
-
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
-
Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.
-
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
-
Poverty, process of care, and outcome in acute coronary syndromes.
-
Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.
-
Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
-
Prescriber Continuity and Disease Control of Older Adults.
-
Prescriber continuity and medication adherence for complex patients.
-
Primary Prevention of Heart Failure in Women.
-
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
-
Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program.
-
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review.
-
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
-
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.
-
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
-
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
-
Reperfusion for acute myocardial infarction: is the future in plastics?
-
Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease.
-
Reply: Personalize and Optimize Lipid-Lowering Therapies.
-
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
-
Safety considerations with gastrointestinally active lipid-lowering drugs.
-
Safety considerations with niacin therapy.
-
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.
-
Sirolimus monotherapy following Campath-1H induction.
-
Study protocol: Couples Partnering for Lipid Enhancing Strategies (CouPLES) - a randomized, controlled trial.
-
Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT.
-
Systemic management of diabetic retinopathy.
-
Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.
-
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
-
Temporal changes in the external validity of clinical trials: asymptomatic carotid artery stenosis.
-
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
-
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
-
The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
-
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
-
The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids.
-
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
-
The next 10 years in personalized medicine in cardiology.
-
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative.
-
The use of lipid-lowering drugs in children.
-
Therapy and clinical trials.
-
Treatment of hyperlipidemia with combined niacin-statin regimens.
-
Treatment of type III hyperlipoproteinemia.
-
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
-
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
-
Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.
-
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
-
Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
-
Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators.
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG).
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
-
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
-
Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study.
-
Keywords of People